لاتفيا - اللاتفية - Zāļu valsts aģentūra

vale pharmaceuticals limited, ireland - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 875 mg/125 mg

الاتحاد الأوروبي - اللاتفية - EMA (European Medicines Agency)

gilead sciences ireland uc - aztreonam lizīns - cystic fibrosis; respiratory tract infections - antibakteriālas līdzekļi sistēmiskai lietošanai, - cayston ir indicēts pseudomonas aeruginosa izraisītu hronisku plaušu infekciju nomācošai terapijai pacientiem ar cistisko fibrozi (cf) vecumā no 6 gadiem. jāņem vērā oficiālās vadlīnijas par piemērotu izmantot antibakteriālas vielas.

الاتحاد الأوروبي - اللاتفية - EMA (European Medicines Agency)

pfizer europe ma eeig - anidulafungin - candidiasis - antimycotics sistēmiskai lietošanai - Ārstēšanā invazīvās kandidoze pieaugušajiem un pediatrijas pacienti vecumā no 1 mēneša līdz 18 gadiem.

الاتحاد الأوروبي - اللاتفية - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinibs - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

الاتحاد الأوروبي - اللاتفية - EMA (European Medicines Agency)

merck sharp and dohme b.v - posaconazole - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics sistēmiskai lietošanai - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 un 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 un 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness ir definēta kā progresēšanu infekcijas vai nespēja uzlabot pēc vismaz 7 dienas pirms terapijas devas efektīvs pretsēnīšu terapija. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 un 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 un 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 un 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness ir definēta kā progresēšanu infekcijas vai nespēja uzlabot pēc vismaz 7 dienas pirms terapijas devas efektīvs pretsēnīšu terapija. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 un 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 un 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness ir definēta kā progresēšanu infekcijas vai nespēja uzlabot pēc vismaz 7 dienas pirms terapijas devas efektīvs pretsēnīšu terapija. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invazīvās aspergillosis pacientiem ar slimību, kas ir ugunsizturīgi, lai amfotericīna b vai itraconazole, vai pacientiem, kuri nepanes no šīm zālēm;- fusariosis pacientiem ar slimību, kas ir ugunsizturīgi, lai amfotericīna b, vai pacientiem, kuri nepanes no amfotericīna b;- chromoblastomycosis un mycetoma pacientiem ar slimību, kas ir ugunsizturīgi, lai itraconazole, vai pacientiem, kuri nepanes no itraconazole;- coccidioidomycosis pacientiem ar slimību, kas ir ugunsizturīgi, lai amfotericīna b, itraconazole vai fluconazole, vai pacientiem, kuri nepanes no šīm zālēm;- orofaringālas kandidoze: kā pirmās līnijas terapija pacientiem, kuriem ir smagas slimības vai pat cilvēkiem ar traucētu imūnsistēmu, kuriem atbildes uz aktuāliem terapija ir sagaidāms, ka būs slikti. refractoriness ir definēta kā progresēšanu infekcijas vai nespēja uzlabot pēc vismaz 7 dienas pirms terapijas devas efektīvs pretsēnīšu terapija. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

الاتحاد الأوروبي - اللاتفية - EMA (European Medicines Agency)

pari pharma gmbh - tobramicīns - cystic fibrosis; respiratory tract infections - antibakteriālas līdzekļi sistēmiskai lietošanai, , aminoglycoside antibakteriālas - vantobra ir indicēts hroniskas plaušu infekcijas ārstēšanai pseudomonas aeruginosa dēļ 6 gadus veciem un vecākiem pacientiem ar cistisko fibrozi (cf). jāņem vērā oficiālās vadlīnijas par piemērotu izmantot antibakteriālas vielas.

الاتحاد الأوروبي - اللاتفية - EMA (European Medicines Agency)

pfizer europe ma eeig - voriconazole - candidiasis; mycoses; aspergillosis - antimycotics sistēmiskai lietošanai - voriconazole, ir plaša spektra, triazola pretsēnīšu līdzeklis un tiek norādīts pieaugušajiem, gan bērniem, vecumā no 2 gadiem un iepriekš šādi:ārstēšanā invazīvās aspergillosis;attieksme pret candidaemianon-neutropenic pacientiem;ārstēšana fluconazole-izturīgs smagu invazīvo candida infekcijas (tostarp c. krusei);Ārstēšana smagu sēnīšu infekcijas, ko izraisa scedosporium spp. un fusarium spp. vfend būtu jāievada galvenokārt pacientiem ar progressive, iespējams, dzīvībai bīstamas infekcijas. profilakses invazīvās sēnīšu infekcijas, augstu riska alogēnas asinsrades cilmes šūnu transplantācija (hsct) saņēmējiem.

لاتفيا - اللاتفية - Zāļu valsts aģentūra

queisser pharma gmbh & co. kg, germany - crataegi augļu ekstrakts šķidruma, crataegi augļu ekstrakts šķidruma, melissae folii iegūt šķidrums, rosmarini folii iegūt šķidrums, valerianae saknes ekstrakts šķidrais - Šķidrums iekšķīgai lietošanai

لاتفيا - اللاتفية - Zāļu valsts aģentūra

medochemie ltd., cyprus - amoxicillinum, skābes clavulanicum - pulveris iekšķīgi lietojamas suspensijas pagatavošanai - 250 mg/62,5 mg/5 ml

لاتفيا - اللاتفية - Zāļu valsts aģentūra

grindeks, as, latvia - sulfadiazīna sudraba sāls - ziede - 10 mg/g